Silver Book Fact

Flu vaccine use reduces disease burden

Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also reduced the days of illness by 23% to 27% depending on severity of illness, lost work days by 18% to 28%, and days with visits to health care professionals by 25% to 41%.

Nichol, Kristin L., April Lind, Karen L. Margolis, Maureen Murdoch, Rodney McFadden, et al. The Effectiveness of Vaccination Against Influenza in Healthy, Working Adults. NEJM. 1995; 333(14): 889-93. http://www.nejm.org/doi/full/10.1056/NEJM199510053331401

Reference

Title
The Effectiveness of Vaccination Against Influenza in Healthy, Working Adults
Publication
NEJM
Publication Date
1995
Authors
Nichol, Kristin L., April Lind, Karen L. Margolis, Maureen Murdoch, Rodney McFadden, et al.
Volume & Issue
Volume 333, Issue 14
Pages
889-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
  • Flu vaccine use reduces disease burden
    Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also…  
  • Reduction in hospital-acquired HAIs could produce significant savings
    Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up…  
  • Life years saved from infectious disease eradication
    Infectious disease eradication in the U.S. led to the following annual life years saved (LYS): 5,811,852 for measles 42,702 for tetanus 212,690 for polio 1,685,740 for smallpox  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.